- Home
- MRVI vs RNAC Comparison
MRVI vs RNAC Comparison
Compare MRVI & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRVI
- RNAC
- Stock Information
- Founded
- MRVI 2014
- RNAC 2007
- Country
- MRVI United States
- RNAC United States
- Employees
- MRVI 560
- RNAC N/A
- Industry
- MRVI Biotechnology: Pharmaceutical Preparations
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- MRVI Health Care
- RNAC Health Care
- Exchange
- MRVI Nasdaq
- RNAC Nasdaq
- Market Cap
- MRVI 350.1M
- RNAC 276.3M
- IPO Year
- MRVI 2020
- RNAC 2016
- Fundamental
- Price
- MRVI $2.42
- RNAC $10.05
- Analyst Decision
- MRVI Hold
- RNAC Strong Buy
- Analyst Count
- MRVI 10
- RNAC 4
- Target Price
- MRVI $5.84
- RNAC $40.00
- AVG Volume (30 Days)
- MRVI 1.5M
- RNAC 48.4K
- Earning Date
- MRVI 08-11-2025
- RNAC 08-07-2025
- Dividend Yield
- MRVI N/A
- RNAC N/A
- EPS Growth
- MRVI N/A
- RNAC N/A
- EPS
- MRVI N/A
- RNAC N/A
- Revenue
- MRVI $219,830,000.00
- RNAC $1,026,000.00
- Revenue This Year
- MRVI N/A
- RNAC N/A
- Revenue Next Year
- MRVI $7.23
- RNAC N/A
- P/E Ratio
- MRVI N/A
- RNAC N/A
- Revenue Growth
- MRVI N/A
- RNAC N/A
- 52 Week Low
- MRVI $1.67
- RNAC $8.46
- 52 Week High
- MRVI $9.60
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- MRVI 49.60
- RNAC 34.71
- Support Level
- MRVI $2.28
- RNAC $10.50
- Resistance Level
- MRVI $2.47
- RNAC $11.80
- Average True Range (ATR)
- MRVI 0.14
- RNAC 0.56
- MACD
- MRVI -0.01
- RNAC -0.11
- Stochastic Oscillator
- MRVI 27.45
- RNAC 0.45
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.